NewAmsterdam Pharma (NAMS) said late Wednesday it has priced an underwritten public offering of 12.1 million shares at $24.50 per share and pre-funded warrants to purchase 4.9 million shares at $24.4999 per warrant.
The company said it has also granted underwriters a 30-day option to purchase up to 2.6 million additional shares
The company said it expects gross proceeds from the offering, anticipated to close on Thursday, of $416.5 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。